Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AstraZeneca PLC, Teva Pharmaceutical Industries Ltd Seek To Buy Amarin Corporation PLC-Reuters
Reuters reported that Teva Pharmaceutical Industries Ltd is a leading candidate to buy Amarin Corporation PLC the Calcalist financial daily reported. Calcalist said British drugmaker AstraZeneca PLC was also looking to buy Amarin, which has a market value on Nasdaq of $1.6 billion. A spokeswoman for Israel-based Teva said the company did not comment on rumours.
Latest Developments for AstraZeneca PLC
- AstraZeneca PLC To Acquire Pearl Therapeutics To Strengthen Respiratory Portfolio
- AstraZeneca PLC Announces Results from Phase III OSKIRA Trials of Fostamatinib and Decides to Return Rights to Compounds to Rigel Pharmaceuticals
- AstraZeneca PLC To Acquire Omthera Pharmaceuticals Inc
- AstraZeneca PLC Reaffirms FY 2013 Guidance-Conference Call
Latest Key Developments in Pharmaceuticals
- Glenmark Pharmaceuticals Ltd Receives Final ANDA Approval For Riluzole Tablets, 50mg
- Valeant Pharmaceuticals International Inc's VPII Escrow Corp Announces Launch Of Private Offering Of Senior Notes
- Hubei Guangji Pharmaceutical Co Ltd to Acquires 35% Stake in Subsidiary
- Valeant Pharmaceuticals International Inc Prices Public Offering Of Common Shares
- Share this
- Link this
- Digg this
Follow Reuters